{"id":"NCT05030311","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-30","primaryCompletion":"2023-12-27","completion":"2024-01-19","firstPosted":"2021-09-01","resultsPosted":"2024-12-02","lastUpdate":"2025-04-08"},"enrollment":470,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria"],"interventions":[{"type":"DRUG","name":"LOU064 25 mg (b.i.d)","otherNames":["remibrutinib"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"LOU064 25 mg (b.i.d) as a tablet.","otherNames":["remibrutinib"]}],"arms":[{"label":"LOU064 25mg b.i.d.","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo.","primaryOutcome":{"measure":"Change From Baseline in Weekly Urticaria Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint)","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"LOU064 25mg b.i.d.","deltaMin":-20.02,"sd":0.716},{"arm":"Placebo","deltaMin":-13.79,"sd":0.98}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":9},"locations":{"siteCount":112,"countries":["United States","Argentina","Australia","Bulgaria","Colombia","Czechia","France","Hungary","India","Italy","Japan","Mexico","Puerto Rico","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["40043237"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=2429"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":309},"commonTop":["COVID-19","Headache","Nasopharyngitis","Urinary tract infection","Urticaria"]}}